From breakthrough discovery to real-world impact

Fibraxis is a pioneering spin-out company originating from extensive research conducted in Dr. Jill Johnson’s laboratory at Aston University, Birmingham. As dedicated biomedical researchers, our passion is uncovering the cellular and molecular mechanisms underlying disease. Our work led to the discovery of a previously unexplored pathway in asthma, revealing a novel therapeutic target with the potential to transform treatment approaches.

Further investigation within our laboratory demonstrated that our identified drug candidate exhibited remarkable efficacy, far exceeding expectations. Recognising its potential to significantly improve asthma management, we made the pivotal decision to transition our research from the lab to the marketplace. This marked the beginning of our journey in translating scientific innovation into real-world impact.

With a steadfast commitment to bringing groundbreaking treatments to patients, Fibraxis is focused on the commercialisation of this novel drug. Our goal is to provide asthma sufferers with a transformative new therapy, offering them improved quality of life and a future with better disease control.